BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17868422)

  • 1. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
    Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG
    BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
    Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
    Khoddami SM; Shariat SF; Lotan Y; Saboorian H; McConnell JD; Sagalowsky AI; Roehrborn CG; Koeneman KS
    BJU Int; 2004 Jul; 94(1):42-6. PubMed ID: 15217428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
    Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.
    Shariat SF; Khoddami SM; Saboorian H; Koeneman KS; Sagalowsky AI; Cadeddu JA; McConnell JD; Holmes MN; Roehrborn CG
    J Urol; 2004 Mar; 171(3):1122-7. PubMed ID: 14767284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
    BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and prognostic role of syndecan-2 in prostate cancer.
    Popović A; Demirović A; Spajić B; Stimac G; Kruslin B; Tomas D
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):78-82. PubMed ID: 19786981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
    Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
    Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
    J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
    Freedland SJ; Grubb KA; Yiu SK; Humphreys EB; Nielsen ME; Mangold LA; Isaacs WB; Partin AW
    J Urol; 2005 Sep; 174(3):919-22. PubMed ID: 16093988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
    Guzzo TJ; Vira MA; Neway W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
    Urology; 2007 Jun; 69(6):1147-51. PubMed ID: 17572204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy.
    Fujita K; Nakayama M; Nakai Y; Takayama H; Nishimura K; Ujike T; Nishimura K; Aozasa K; Okuyama A; Nonomura N
    Cancer Sci; 2009 Jun; 100(6):1047-50. PubMed ID: 19385972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
    Brimo F; Vollmer RT; Friszt M; Corcos J; Bismar TA
    BJU Int; 2010 Aug; 106(3):418-23. PubMed ID: 20002675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.